A Digital Twin of Canagliflozin Pharmacokinetics and Pharmacodynamics in Type 2 Diabetes Mellitus
Preprint
- 27 January 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Canagliflozin is an SGLT2 inhibitor prescribed for the management of type 2 diabetes mellitus, lowering blood glucose by increasing urinary glucose excretion (UGE). However, pharmacokinetic (PK) and pharmacodynamic (PD) responses vary across patient populations, complicating dose selection under altered organ function. Here, we developed a whole-body PBPK/PD digital twin of canagliflozin that integrates absorption, distribution, metabolism, and excretion, and explicitly models renal glucose handling. The model represents canagliflozin and its major metabolites (M5, M7, M9) and was calibrated and evaluated using curated PK/PD data from 22 clinical studies spanning healthy individuals, patients with type 2 diabetes, and cohorts with renal or hepatic impairment. Simulations reproduced dose-dependent exposure and UGE across single- and multiple-dose regimens. Renal impairment produced modest changes in parent drug exposure but markedly reduced UGE and increased metabolite exposure, consistent with reduced glucose filtration and impaired metabolite clearance. Under hepatic impairment, simulations predicted increased canagliflozin exposure with altered metabolite profiles, while PD effects were minimal, although evaluation was limited by sparse clinical PD endpoints. All model files, simulation scripts, and curated datasets are provided in open SBML workflows in accordance with FAIR principles, enabling reproducible simulations and reuse for model-informed analyses of canagliflozin PK/PD variability.Keywords
All Related Versions
This publication has 60 references indexed in Scilit:
- A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitorsCPT: Pharmacometrics & Systems Pharmacology, 2023
- Mechanistic evaluation of the effect of sodium‐dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamicsBiopharmaceutics & Drug Disposition, 2020
- Glucose transporters in the kidney in health and diseasePflügers Archiv - European Journal of Physiology, 2020
- Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubulesBiopharmaceutics & Drug Disposition, 2016
- In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humansThe Journal of Clinical Pharmacology, 2015
- Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, and assessment of dose proportionality in healthy participantsClinical Pharmacology in Drug Development, 2014
- Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participantsClinical Pharmacology in Drug Development, 2014
- Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participantsClinical Pharmacology in Drug Development, 2014
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes MellitusThe Journal of Clinical Pharmacology, 2013
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973